What GLP-1s Actually Cost Your Company: Consumer Prices vs. Employer Reality

You've seen the headlines. Wegovy for $149 a month. Zepbound for $299. Lilly's new pill, Foundayo, starting at $149. If you're a benefits director reading those numbers, you might think the GLP-1 cost crisis is solving itself.

It isn't. Those are consumer self-pay prices — what an individual pays out of pocket through manufacturer direct-to-consumer programs like NovoCare and LillyDirect. They have almost nothing to do with what your self-insured plan actually pays when a member fills a GLP-1 prescription through your pharmacy benefit.

Here's the same drug at five different price points:

That gap isn't unique to Wegovy — it exists across every major GLP-1 formulation, and the annual dollar differences are staggering.

The number your PBM isn't volunteering

The most rigorous estimate of what employers actually pay for GLP-1s comes from the Employee Benefit Research Institute, in collaboration with Blue Cross Blue Shield and Blue Health Intelligence. Their October 2025 Issue Brief (#644) analyzed real claims data and found that the net cost of GLP-1 medications to employers — after discounts and rebates — runs $617 to $766 per 30-day supply. A separate analysis published in Obesity in 2024 using manufacturer discount data landed in a similar range, corroborating the EBRI findings.

So while a consumer can walk into Costco and get Wegovy through NovoCare for $349 a month, or pick up Foundayo on LillyDirect for $149, the employer running that same medication through a PBM contract is likely paying two to four times more.

How is that possible? The short answer: rebates don't work the way most people assume they do.

The rebate structure that benefits everyone except you

Wholesale acquisition cost — the sticker price — for Wegovy is $1,349 per month. Ozempic runs about $1,027. Zepbound is $1,086. Foundayo launched at $649 (Fierce Pharma, April 2026, citing Jefferies). These are the prices PBMs use as a starting point for negotiations.

PBMs negotiate rebates from manufacturers in exchange for favorable formulary placement. Those rebates are supposed to bring the price down. And they do — but not as much as you might think, and not always in ways that flow through to the plan sponsor.

Sequoia Consulting put it plainly in their November 2025 employer FAQ: employers often have limited visibility into how rebates are calculated or retained, making it difficult to understand the true net cost. WTW's 2025 Best Practices Survey found something worse: rebates on GLP-1 weight loss drugs aren't actually driving competition between manufacturers — they're stifling it, because most formularies already cover both Wegovy and Zepbound.

WTW also found that in most cases, requiring members to enroll in a lifestyle modification program or limiting prescribing to specialists results in a loss of rebates for GLP-1 weight loss drugs. Read that again. The clinical management strategies most employers would instinctively reach for — the ones that sound responsible — can actually increase your net cost per prescription by disqualifying you from manufacturer rebate tiers.

Mercer acknowledged this dynamic in their 2026 GLP-1 guidance, noting that implementing certain utilization management strategies could disqualify businesses from rebates. They also offered a telling suggestion: employers should ask their PBMs how the direct-to-consumer options compare, because they may find that their net-of-rebate price is comparable to, or even better than, the direct-to-consumer price. The implication is that many employers haven't asked — and many PBMs aren't volunteering the answer.

The numbers behind the noise

To appreciate the scale, consider what's actually happening to employer pharmacy budgets. WTW's Rx Collaborative data shows GLP-1 per-member-per-month costs went from roughly $1.50 in 2019 to over $27 in the first quarter of 2025. Five GLP-1 drugs now account for 21% of total pharmacy spend after estimated rebates and discounts (WTW, April 2025). Evernorth's 2025 report found that GLP-1s drove nearly 47% of total drug spending growth in 2024.

The Peterson-KFF Health System Tracker published employer focus groups in late 2025 spanning over 100 companies and 250,000 workers. The quotes tell the story better than any chart. One HR director reported that GLP-1s went from number 32 to number one in pharmacy spending in a single year. A compensation manager at a large retailer described spending half a million dollars and being projected to hit $1.2 million the following year. A benefits manager at another retailer described pulling the entire anti-obesity drug category because rebates got dramatically worse and costs were skyrocketing.

EBRI modeled the premium impact: at real-world net costs of $617–$766 per month, employer premiums increase by 5.3% to 13.8%, depending on adherence and eligibility assumptions. If those net costs dropped to $200 per month — a hypothetical future scenario — the increase shrinks to 1.0%–3.9%.

We are nowhere near $200 per month through the traditional pharmacy benefit channel. To put those percentages in plan-level dollars: a 3,000-employee self-insured plan with 4% GLP-1 utilization — 120 members on therapy — is spending approximately $1 million per year on GLP-1s alone at the EBRI midpoint of ~$690 per month net. That's the line item behind the 5–14% premium increase your CFO is asking about. If utilization climbs to 8% as oral options expand access, that becomes $2 million. These are pharmacy-only figures; they don't include the medical claims, care management overhead, or PBM administrative fees that ride alongside them.

Why consumer prices won't fix employer costs

Novo Nordisk announced in February 2026 that it will cut the wholesale acquisition cost of all semaglutide products to $675 per month effective January 1, 2027 — roughly a 50% reduction for Wegovy. Foundayo launched in April 2026 with a WAC of $649, already near that level.

This sounds like relief. But the WAC cut changes the starting point for PBM negotiations. It does not automatically translate into proportional savings at the plan level. Citi analyst Geoffrey Meacham noted that the price cut will likely benefit a relatively small portion of new prescriptions compared to cash-pay channels, which hold the larger share (Reuters, March 2026). And Novo explicitly stated that these WAC changes do not impact direct-to-patient self-pay prices — because those prices are already lower.

Meanwhile, some employers are beginning to explore an end-run around the whole system: subsidizing employees' direct purchases from manufacturers rather than routing claims through PBMs at all. WorldatWork reported in July 2025 that some employers are contributing to lifestyle spending accounts so employees can buy GLP-1s through cash-pay programs. The logic is simple, if uncomfortable: the cash-pay price of $149–$349 per month may actually be lower than what the employer pays through the traditional pharmacy benefit after accounting for PBM fees and retained rebates.

That this is even a consideration tells you everything about how broken the current pricing structure is.

The cost-offset argument isn't holding up yet

Even at these prices, the investment would be easier to justify if GLP-1s delivered durable, measurable savings downstream. So far, the data says otherwise. Prime Therapeutics' three-year analysis, presented in March 2026, found that only 8.1% of commercially insured patients without diabetes remained on GLP-1 therapy at three years. And for those who did use them, Prime found no medical cost offsets — total costs for the GLP-1 treatment group actually increased by an average of $1,338 per member compared to a matched control group (Managed Healthcare Executive, March 2026). Mercer acknowledges directly that more research is needed on whether downstream savings materialize. That research is worth watching, but it shouldn't be the basis for this year's coverage decision.

What changes next

Two developments will reshape this landscape, though neither as quickly as employers need.

First, the Consolidated Appropriations Act of 2026 (P.L. 119-75), signed February 3, 2026, mandates 100% rebate pass-through for all ERISA plans and requires drug-level reporting from PBMs, with penalties of $10,000 per day for disclosure failures and $100,000 per item of false information (Morgan Lewis, February 2026; Reinhart Law, March 2026). Most provisions take effect 30 months after enactment — January 1, 2029 for calendar-year plans — though the expanded service provider disclosure requirements under ERISA §408(b)(2) appear to apply to contracts entered into or renewed after February 3, 2026. A separate DOL proposed rule could accelerate some disclosure requirements for self-funded plans as early as mid-2026, but the full statutory rebate pass-through and reporting mandates are a 2029 story. This legislation should eventually close the gap between what employers think they pay and what they actually pay — but "should" and "eventually" are both doing a lot of work in that sentence.

Second, the oral GLP-1 pipeline will expand the pool of eligible and willing patients. Foundayo's lower WAC ($649 vs. $1,349 for Wegovy) and no-food-restriction dosing could put downward pressure on the class. But William Blair analysts estimate injectables will retain about 80% of the branded obesity market share (Fierce Pharma, April 2026), and oral options may pull in needle-averse patients who previously opted out. Whether utilization expands faster than prices fall is the open question.

For benefits directors at self-insured employers, the immediate action is simpler than either of those macro shifts: find out what you're actually paying. Not the WAC. Not the consumer price. Not what your PBM's quarterly report implies. The actual, net, all-in cost per GLP-1 prescription flowing through your plan — and how that compares to what your employees could pay on their own through a manufacturer program.

If you don't know that number, you can't make a rational decision about coverage design. And right now, most employers don't know it.